A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease | Zendy

Martin R. Farlow | Zendy; Richard E. Thompson | Zendy; LeeJen Wei | Zendy; Alan J. Tuchman | Zendy; Elaine Grenier | Zendy; David Crockford | Zendy; Susanne Wilke | Zendy; Jeffrey Benison | Zendy; Daniel L. Alkon | Zendy

Open Access

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease

Author(s) -

Martin R. Farlow,

Richard E. Thompson,

LeeJen Wei,

Alan J. Tuchman,

Elaine Grenier,

David Crockford,

Susanne Wilke,

Jeffrey Benison,

Daniel L. Alkon

Publication year - 2018

Publication title -

journal of alzheimer s disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.677

H-Index - 139

eISSN - 1875-8908

pISSN - 1387-2877

DOI - 10.3233/jad-180759

Subject(s) - tolerability , placebo , double blind , medicine , alzheimer's disease , randomized controlled trial , psychology , disease , adverse effect , alternative medicine , pathology

Bryostatin-activated PKC epsilon pre-clinically induces synaptogenesis, anti-apoptosis, anti-amyloid-β oligomers, and anti-hyperphosphorylated tau.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research